

P21010.A02

## TECH CENTER 1600/2900 EMARK OFFICE Group Art Unit: 1614 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant

: Kanji TAKADA

Serial No

: 09/831,901

(National Stage of PCT/JP99/06602)

Examiner: Unknown

I. A. Filed

: November 26, 1999

For

: AN ORAL FORMULATION FOR GASTROINTESTINAL

DRUG DELIVERY

## INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicant hereby brings the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification and in the International Search Report, the International Preliminary Examination Report, and the Written Opinion issued in connection with counterpart International Application No. PCT/JP99/06602. Copies of the International Search Report, the International Preliminary Examination Report, and the Written Opinion were submitted when entering the National Stage.

U.S. Patent No. 4,765,983;

U.S. Patent No. 5,236,713;

## P21010.A02

WO 98/24412;

"Pharmaceutical Research", Vol. 2, pp. 397-405 (1995);

Takada, "Pharm. Tech. Japan", pp. 1299-1307 (1988);

Takada, "Pharm. Tech. Japan", pp. 512-515, 518-521 (1991);

Takada, "Pharm. Tech. Japan", pp. 1335-1344 (1995);

Ko et al., Nippon Rinsho, "Japan Clinicals", pp. 595-600 (1998), (with English language abstract); and

Ohyama Takao et al., "Ishoku [Transplantation], Vol. 34, No. 4, pp. 174-185 (1999), (with English language abstract).

Two documents not cited in the specification are also brought to the attention of the Examiner in charge of the above identified application.

Takada, "Pharm. Tech. Japan", 1995, pp. 903-913; and

Takada, "Pharm. Tech Japan", 1995, pp. 1035-1042.

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449, as well as the International Preliminary Examination Report, the International Search Report, and the Written Opinion. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

## P21010.A02

Applicants note that an Office Action on the Merits has not issued in the instant application. However, if an Office Action on the Merits has issued, and is crossing this statement in the mail, the undersigned hereby authorizes the Commissioner to charge any fee necessary for consideration of this statement, including any payment under 37 C.F.R. 1.17(p), to be charged to Applicant's Deposit Account No. 19-0089...

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully submitted,

Kanji TAKAD

Bruce H. Bernstein

-Jepno. 33, 094

Reg. No. 29,027

October 2, 2001 GREENBLUM & BERNSTEIN, P.L.C. 1941 Roland Clarke Place Reston, VA 20191 (703) 716-1191